Is there any information on the use of the new migraine e medication, Emgality (galcanezumab-gnlm) while nursing? It is a CGRP antagonist recently approved for use for migraine management manufactured by Eli Lilly. Any information would be much appreciated.
Announcement
Collapse
No announcement yet.
Emgality and breastfeeding
Collapse
X
-
Pfoise:
Galcanezumab-gnlm (Emgality) is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. It is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. As an IgG4, levels in milk are believed to be higher than those of IgG1 monoclonal antibodies. At this time we do not know the rate of transfer of this specific IgG4 monoclonal antibody, but some is likely to penetrate into human milk.
That said, plasma levels in the newborn are likely to be significant, because of its transfer in the third trimester.
As an IgG, it is unlikely to survive the proteases in the GI tract and little is believed to be absorbed after delivery. I think the risk to the infant is low, but is yet to be determined.
Tom Hale Ph.D.
Comment
Comment